登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>IFN-gamma >IFN-M414

Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H6)

抗体来源(Source)

Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H6) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.

克隆号(Clone)

13E6H6

亚型(Isotype)

Human IgG1/kappa

偶联(Conjugate)

Unconjugated

抗体类型(Antibody Type)

Recombinant Monoclonal

种属反应性(Reactivity)

Human

免疫原(Immunogen)

Recombinant Human IFNγ is expressed from human HEK293 cells.

特异性(Specificity)

This product is a specific antibody specifically reacts with IFN-γ, Human. No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

应用(Application)

ApplicationRecommended Usage
ELISA0.1-20 ng/mL

纯度(Purity)

>95% as determined by SDS-PAGE.

纯化(Purification)

Protein A purified/ Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

IFN-gamma SDS-PAGE

Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H6) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

IFN-gamma ELISA

Immobilized Human IFN-gamma, premium grade (Cat. No. IFG-H4211) can bind Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6) (Cat. No. IFN-M414) with a linear range of 0.07-0.63 ng/mL (QC tested). No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

Protocol

 

活性(Bioactivity)-SPR

IFN-gamma SPR

Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6) (Cat. No. IFN-M414) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IFN-gamma, premium grade (Cat. No. IFG-H4211) with an affinity constant of 0.11 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

IFN-gamma BLI

Loaded Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M414) on AHC Biosensor, can bind Human IFN-gamma, premium grade (Cat. No. IFG-H4211) with an affinity constant of 0.718 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Interferon-gamma (IFN-γ/IFNG) is a dimerized soluble cytokine that is the only member of the type II class of interferon. This interferon was originally called macrophage-activating factor, a term now used to describe a larger family of proteins to which IFN-γ belongs. IFN-gamma has been used in a wide variety of clinical indications. Interferon-gamma (IFNgamma) is a central regulator of the immune response and signals via the Janus Activated Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway. Interferon gamma has broader roles in activation of innate and adaptive immune responses to viruses and tumors, in part through upregulating transcription of genes involved in cell cycle regulation, apoptosis, and antigen processing/presentation. Despite this, rodent and human trophoblast cells show dampened responses to IFNG that reflect the resistance of these cells to IFNG-mediated activation of major histocompatibility complex (MHC) class II transplantation antigen expression.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IFN-gamma靶点信息
英文全称:Interferon gamma
中文全称:干扰素-γ
种类:Homo sapiens
上市药物数量:3详情
临床药物数量:9详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定